Core Laboratories N.V.
NYSE:CLBOil & Gas Equipment & Services
+$0.12 today
- Market cap
- $387.21M
- Beta
- 0.99
- P/E (TTM)
- 18.3
- EPS (TTM)
- $0.63
- Dividend yield
- 0.35%
Volume 0.52M
Average 0.49M
CLB EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Core Laboratories N.V.NYSE: CLB
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA dips below year-ago levels
Q1 FY2026 EBITDA of $5.65M fell 30.5% year over year, behind the +4.5% change in trailing-twelve-month EBITDA. Sequentially, it fell 71.0% from the prior quarter. Over 3 fiscal years it compounded at +6.6% a year.
Context
- EBITDA amounted to 13.5% of revenue in FY2025, down 0.5 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of $58.43M (-17.8%) for the fiscal year ending Dec 2026, a slowdown from the -3.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5.65M-71.0% QoQ
- Last fiscal yearDec 2025
- $71.12M-3.3% YoY
- LTMMar 2026
- $72.35M+4.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -30.5% | -44.4% | -13.8 pp |
| 1 year | -3.3% | -17.8% | -14.6 pp |
| 3-year CAGR | +6.6% | +7.2% | +0.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 71.12M USD
- Year-over-year change
- -3.3%
- 4-year CAGR
- +2.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 71.12M | -3.3% |
| FY2024 | 2024-12-31 | 73.51M | +4.4% |
| FY2023 | 2023-12-31 | 70.42M | +20.0% |
| FY2022 | 2022-12-31 | 58.69M | -8.0% |
| FY2021 | 2021-12-31 | 63.78M | — |
EBITDA vs competitors
How CLB compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +4.5% is the 4th highest of 10, against a peer median of -13.5%.
- EBITDA amounts to 13.8% of revenue for CLB, versus a peer median of 42.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.34B USD | +42.2% | +25.5% | 41.4% | |
| LTM Mar 2026 | $455.9M USD | +1.4% | — | 43.4% | |
| LTM Mar 2026 | CA$414.61M CAD | -21.1% | +7.9% | 22.1% | |
| LTM Mar 2026 | $392.85M USD | -51.0% | +3.3% | 51.0% | |
| LTM Mar 2026 | $193.19M USD | +13.8% | +2.0% | 5.3% | |
| LTM Mar 2026 | $191.16M USD | -13.5% | -10.6% | 42.0% | |
| LTM Mar 2026 | $124.81M USD | -15.7% | -2.2% | 45.3% | |
| LTM Mar 2026 | $72.35M USD | +4.5% | +6.6% | 13.8% | |
| LTM Mar 2026 | $42.05M USD | -56.3% | +29.9% | 11.8% | |
| LTM Mar 2026 | -$381.18M USD | +17.0% | — | 29990.6% | |
| Peer median (excluding CLB) | — | -13.5% | +3.3% | 42.0% | |
Competitors are the stored peer set for CLB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 470.25M | 489.74M | 509.79M | 523.85M | 526.52M |
| Cost of Revenue | 386.41M | 410.82M | 415.74M | 435.48M | 432.24M |
| Gross Profit | 83.84M | 78.92M | 94.05M | 88.37M | 94.28M |
| Gross Margin | 17.8% | 16.1% | 18.4% | 16.9% | 17.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 44.17M | 38.12M | 38.89M | 38.59M | 44.23M |
| Operating Expenses | 38.58M | 37.4M | 39.41M | 29.82M | 43.8M |
| Depreciation & Amortization | 18.52M | 17.16M | 15.78M | 14.95M | 14.65M |
| EBITDA | 63.78M | 58.69M | 70.42M | 73.51M | 71.12M |
| EBITDA Margin | 13.6% | 12.0% | 13.8% | 14.0% | 13.5% |
| Operating Income | 45.26M | 41.52M | 54.64M | 58.56M | 50.49M |
| Operating Margin | 9.6% | 8.5% | 10.7% | 11.2% | 9.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 9.15M | 11.57M | 13.43M | 12.37M | 10.57M |
| Other Income / Expenses | (9.15M) | (11.57M) | (13.43M) | (12.37M) | (4.59M) |
| Income Before Tax | 36.11M | 29.95M | 41.21M | 46.19M | 45.9M |
| Pre-Tax Margin | 7.7% | 6.1% | 8.1% | 8.8% | 8.7% |
| Income Tax Expense | 15.89M | 10.3M | 4.19M | 14.03M | 15.51M |
| Net Income | 19.73M | 19.45M | 36.68M | 31.4M | 29.67M |
| Net Margin | 4.2% | 4.0% | 7.2% | 6.0% | 5.6% |
| EPS (Basic) | 0.43 | 0.42 | 0.79 | 0.67 | 0.68 |
| EPS (Diluted) | 0.42 | 0.42 | 0.77 | 0.66 | 0.68 |
| Weighted Avg Shares | 46.01M | 46.33M | 46.68M | 46.9M | 46.5M |
| Weighted Avg Shares (Diluted) | 46.69M | 46.81M | 47.52M | 47.69M | 46.5M |
Core Laboratories N.V.
NYSE:CLB
Intrinsic Alpha fair value
Locked
Current Price
$8.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.